Fig. 1From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysisThe comparison of Kaplan-Meier curves of progression-free survival and cancer-specific survival between metastatic renal cell carcinoma patients receiving immunotherapy (IT) and targeted therapy (TT) in those with metachronous and synchronous metastasesBack to article page